1Calais G,Berger C,Descamps P,et al. Conservative treatment feasibility with induction chemotherapy, surgery, and radiotherapy for patients with breast carcinoma larger than 3cm. Cancer, 1994,74 (4) : 1283 - 1288.
2Goldhirsch A, Glick JH, Gelbet RD, et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Clin Oncol, 2001,19(18) :3817 - 3827.
3Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of woman with operable breast cancer, 1998,16 (8) : 2672 - 2685.
4Goldie JH, Goldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Ther Rep, 1979, 63(11 - 12) : 1727 - 1733.
5Frei E III, Clark JR, Miller D. The concept or neoadjuvant chemotherapy. In SE(ed) :Adjuvant therapy of cancer. Vol V. Orlando, FL: Grune & Stratton, 1987.67.
6Cox CE, Haddad F, Bass S, et al. Lymphatic mapping in the treatment of breast cancer. Oncology, 1998,12(9) : 1283 - 1292.
7Mauriac L, MacGrogan G, Avril A,et al. Neoadjuvant chemotherapy for operable breast carcinoma larger than 3cm: a unicentre randomized trial with a 124-month median follow-up. Ann Oncol, 1999,10 ( 1 ) :47 - 52.
7Chung HC, Rho SY, Kim JH, et al. P-glycoprotein: the intermediate end point of drug presponse to induction chemotherapy in locally advanced breast cancer. Breast Cancer Res Treat, 1997,42(1):65-72.
8Ikeda T. Jinno H, Matsu A, et al. Therole of neoadjuvant Chemotherapy for breast cance trearment, Breast cancer,2002,9(1):8-14.
9Goldie JH, Goldman AJ. A Mathematical model for relating the drag sensitivity of tumors to their spontaneous mution rate Cancer Ther pep. 1979.63(11-12):1727-1733.
10Citro ML,Berry DA,Cirricione C,et al.Randomized trial of dose-dense versus conventionally schedule and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer:first report of intergroup trial C9741/Cancer and leukemia group B trial 9741[J].J Clin Oncol,2003,27(7):1431.
